A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions
Atrial Flutter
Interventions
DRUG

Vernakalant Injection 20 mg/mL

Trial Locations (24)

23219

Medical College of Virginia, Richmond

23249

McGuire VA Medical Center, Richmond

48910

Thoracic and Cardiovascular Institute, Lansing

54449

Marshfield Clinic, Marshfield

95819

Regional Cardiology Associates, Sacramento

T2E 7C5

Heart Health Institute, Rockyview General Hospital, Calgary

T2N 4N1

University of Calgary, Calgary

T6G 2B7

University of Alberta Hospital, Edmonton

L8L 2X2

Hamilton Health Sciences, Hamilton General Hospital, Hamilton

K1Y 4E9

Ottawa Hospitals (Civic & General), Ottawa

H1T 1C8

Institut de Cardiologie de Montreal, Montreal

H2L 4M1

Hopital Notre-Dame du CHUM, Montreal

H2W 1T8

CHUM-Hotel-Dieu de Montreal, Montreal

Unknown

Aalborg University, Aalborg

H:S Bispebjerg Hospital, Copenhagen

Centralsygehuset Esbjerg Varde, Esbjerg

Glostrup Amtssygehus, Glostrup Municipality

Gentofte Amtssygehus, Hellerup

Herlev Amtssygehus, Kardiologisk, Herlev

Sygehus Vendsyssel Hjorring, Hjørring

Holstebro centralsygehus, Holstebro

Hvidovre Hospital, Kardiologisk, Hvidovre

Universitetssjukhuset MAS, Malmo

Centrallasarettet, Vasteras, Västerås

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Advanz Pharma

INDUSTRY